Vericel (VCEL) Set to Announce Earnings on Thursday

Vericel (NASDAQ:VCEL - Get Free Report) will release its earnings data before the market opens on Thursday, November 7th. Analysts expect Vericel to post earnings of ($0.05) per share for the quarter. Investors interested in participating in the company's conference call can do so using this link.

Vericel (NASDAQ:VCEL - Get Free Report) last announced its quarterly earnings data on Thursday, August 1st. The biotechnology company reported ($0.10) EPS for the quarter, meeting analysts' consensus estimates of ($0.10). Vericel had a return on equity of 0.35% and a net margin of 0.37%. The business had revenue of $52.70 million during the quarter, compared to the consensus estimate of $52.59 million. During the same quarter in the previous year, the business earned ($0.11) earnings per share. The business's revenue for the quarter was up 14.8% on a year-over-year basis. On average, analysts expect Vericel to post $0 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Vericel Trading Down 3.3 %

Shares of NASDAQ VCEL traded down $1.50 on Thursday, reaching $44.04. 254,450 shares of the company traded hands, compared to its average volume of 427,160. The stock has a market capitalization of $2.14 billion, a PE ratio of -4,554.00 and a beta of 1.67. Vericel has a fifty-two week low of $32.28 and a fifty-two week high of $54.10. The company has a 50 day moving average of $44.81 and a 200 day moving average of $46.35.

Analyst Ratings Changes

Several analysts have recently issued reports on the stock. Canaccord Genuity Group assumed coverage on shares of Vericel in a research note on Friday, August 9th. They set a "buy" rating and a $57.00 price objective for the company. TD Cowen upped their price target on Vericel from $55.00 to $60.00 and gave the stock a "buy" rating in a research note on Tuesday, August 27th. Stephens lifted their price objective on Vericel from $56.00 to $58.00 and gave the company an "overweight" rating in a research note on Friday, August 2nd. BTIG Research dropped their target price on shares of Vericel from $56.00 to $55.00 and set a "buy" rating for the company in a research report on Monday, July 15th. Finally, StockNews.com cut shares of Vericel from a "hold" rating to a "sell" rating in a research report on Tuesday, October 8th. One analyst has rated the stock with a sell rating and seven have given a buy rating to the company's stock. Based on data from MarketBeat, Vericel has an average rating of "Moderate Buy" and an average target price of $57.71.

Insider Activity

In other news, CEO Dominick Colangelo sold 17,500 shares of the company's stock in a transaction on Wednesday, October 16th. The shares were sold at an average price of $41.38, for a total value of $724,150.00. Following the completion of the transaction, the chief executive officer now directly owns 220,937 shares in the company, valued at approximately $9,142,373.06. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In related news, Director Steven C. Gilman sold 5,833 shares of the company's stock in a transaction on Wednesday, October 16th. The shares were sold at an average price of $41.36, for a total value of $241,252.88. Following the sale, the director now directly owns 11,000 shares of the company's stock, valued at $454,960. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Dominick Colangelo sold 17,500 shares of the firm's stock in a transaction on Wednesday, October 16th. The stock was sold at an average price of $41.38, for a total transaction of $724,150.00. Following the transaction, the chief executive officer now directly owns 220,937 shares of the company's stock, valued at approximately $9,142,373.06. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 29,166 shares of company stock worth $1,200,764 over the last 90 days. Company insiders own 5.20% of the company's stock.

Vericel Company Profile

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns.